🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Finerenone After Catheter Ablation to Reduce Atrial Fibrillation Recurrence

RecruitingPhase 2Ages 18 Years - 80 YearsAllNational Cheng-Kung University Hospital
NCT07799519 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Atrial fibrillation (AF) is a common heart rhythm disorder associated with stroke, heart failure, and increased mortality. Catheter ablation with pulmonary vein isolation (PVI) is an effective rhythm-control strategy, but 20-30% of patients experience AF recurrence within one year. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist with anti-inflammatory, antifibrotic, and metabolic effects, was associated with a lower incidence of AF in prior large trials, and preclinical studies suggest it promotes "browning" of adipose tissue and improves epicardial adipose tissue (EAT) characteristics. This single-center, randomized, investigator-blinded pilot trial will enroll 40 patients undergoing first-time catheter ablation for AF. After successful PVI, participants will be randomized 1:1 to receive finerenone or usual care for 12 months. The primary endpoint is AF recurrence (any

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18-80 years * Atrial fibrillation scheduled for first-time catheter ablation (pulmonary vein isolation) * Estimated glomerular filtration rate (eGFR) \>=25 mL/min/1.73 m2 * Serum potassium \<=5.0 mmol/L Exclusion Criteria: * History of prior catheter-based or surgical pulmonary vein isolation * Current use of other mineralocorticoid receptor antagonists (MRAs) * Severe renal impairment (eGFR \<25 mL/min/1.73 m2) * Serum potassium \>5.0 mmol/L * Severe liver disease (Child-Pugh class C) * Known hypersensitivity to the investigational drug * Contraindications to the investigational drug, such as concomitant use of strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital) * Active cancer or recent chemotherapy * Women who are pregnant, breastfeeding, or planning to become pregnant during the study period
💊

What it tests

  • Finerenone
📍

Where

1 site
National Cheng Kung University Hospital
Tainan, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy